propiomazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2298 362-29-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • largon
  • propiomazine
  • propionylpromethazine
  • propiomazine hydrochloride
  • propiomazine HCl
  • Molecular weight: 340.49
  • Formula: C20H24N2OS
  • CLOGP: 4.91
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 23.55
  • ALOGS: -4.69
  • ROTB: 5

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.45 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 33 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 5, 1960 FDA HIKMA MAPLE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 4723.02 155.72 886 2901 24398 53320881
Intentional overdose 4252.58 155.72 957 2830 66248 53279031
Depressed level of consciousness 590.39 155.72 198 3589 54230 53291049
Tachycardia 279.36 155.72 141 3646 108071 53237208
Fatigue 242.44 155.72 275 3512 730231 52615048
Snoring 175.68 155.72 43 3744 3749 53341530
Akathisia 171.38 155.72 50 3737 8521 53336758

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional self-injury 1671.35 89.90 318 1274 13582 32498352
Intentional overdose 1440.76 89.90 340 1252 41261 32470673
Depressed level of consciousness 161.03 89.90 64 1528 40783 32471151
Tachycardia 112.09 89.90 61 1531 79027 32432907

Pharmacologic Action:

SourceCodeDescription
ATC N05CM06 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Other hypnotics and sedatives
CHEBI has role CHEBI:35717 sedatives
CHEBI has role CHEBI:37930 phenothiazine antipsychotics
CHEBI has role CHEBI:37956 histamine receptor blocker
CHEBI has role CHEBI:48279 5-hydroxytryptamine antagonists
CHEBI has role CHEBI:48561 dopamine blocker
CHEBI has role CHEBI:48876 Antimuskarinika

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
General anesthesia indication 50697003
Local anesthesia indication 386761002
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic
pKa2 1.58 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST WOMBAT-PK CHEMBL
D(2) dopamine receptor GPCR WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR WOMBAT-PK
D(4) dopamine receptor GPCR WOMBAT-PK
D(1A) dopamine receptor GPCR WOMBAT-PK
Alpha-1B adrenergic receptor GPCR WOMBAT-PK

External reference:

IDSource
4019914 VUID
N0000147999 NUI
D02361 KEGG_DRUG
1240-15-9 SECONDARY_CAS_RN
4018031 VANDF
4019914 VANDF
C0033473 UMLSCUI
CHEBI:8491 CHEBI
CHEMBL252103 ChEMBL_ID
CHEMBL1201210 ChEMBL_ID
CHEMBL1201068 ChEMBL_ID
DB00777 DRUGBANK_ID
C084591 MESH_SUPPLEMENTAL_RECORD_UI
4940 PUBCHEM_CID
7284 IUPHAR_LIGAND_ID
735 INN_ID
242Z0PM79Y UNII
227589 RXNORM
1709 MMSL
5371 MMSL
d00914 MMSL
001488 NDDF
001489 NDDF
373493007 SNOMEDCT_US
41324009 SNOMEDCT_US
65868004 SNOMEDCT_US

Pharmaceutical products:

None